规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
靶点 |
Glucagon Receptor
|
---|---|
体外研究 (In Vitro) |
Adomeglivant 不能阻断胰岛的 cAMP 升高作用[2]。 Adomeglivant 对 B 族 GPCR 表现出高性,并与 GluR、GLP-1R 和 GIP-R 中的振荡结合基序电位共振[2]。
|
体内研究 (In Vivo) |
Adomeglivant (5 mg/kg;ip) 在 Avpires-Cre+ 电极中完全消除 CNO (氯氮平-N-氧化物) 的高血压作用。(CNO 是一种心血管的药物兴奋剂,可用于hM3Dq 感应的膜去心肌并增加表达 hM3Dq 的精氨酸加压素 (AVP) 神经元的放电率)[3] 动物模型: Avpires-Cre+ 小鼠[3] 剂量: 5 mg/kg 给药方式: 腹腔注射, CNO 前 30 分钟 结果:完全消除了 CNO 的高血糖作用。
|
参考文献 |
|
分子式 |
C32H36F3NO4
|
---|---|
分子量 |
555.6278
|
精确质量 |
555.26
|
元素分析 |
C, 69.17; H, 6.53; F, 10.26; N, 2.52; O, 11.52
|
CAS号 |
1488363-78-5
|
相关CAS号 |
872260-47-4 (racemic); 488363-78-5 (S-isomer); 872260-19-0 (R-isomer)
|
外观&性状 |
White to off-white solid powder
|
SMILES |
CC1=CC(=CC(=C1C2=CC=C(C=C2)C(C)(C)C)C)O[C@@H](CCC(F)(F)F)C3=CC=C(C=C3)C(=O)NCCC(=O)O
|
InChi Key |
FASLTMSUPQDLIB-MHZLTWQESA-N
|
InChi Code |
InChI=1S/C32H36F3NO4/c1-20-18-26(19-21(2)29(20)23-10-12-25(13-11-23)31(3,4)5)40-27(14-16-32(33,34)35)22-6-8-24(9-7-22)30(39)36-17-15-28(37)38/h6-13,18-19,27H,14-17H2,1-5H3,(H,36,39)(H,37,38)/t27-/m0/s1
|
化学名 |
3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethylphenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid
|
别名 |
LY-2409021; LY2409021; LY 2409021
|
HS Tariff Code |
2934.99.9001
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
DMSO: ~100 mg/mL (~180 mM)
Ethanol: ~100 mg/mL |
---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (4.50 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.7998 mL | 8.9988 mL | 17.9976 mL | |
5 mM | 0.3600 mL | 1.7998 mL | 3.5995 mL | |
10 mM | 0.1800 mL | 0.8999 mL | 1.7998 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
Time course for LS mean (90% CI) change from baseline in HbA1clevel by week and treatment with LY2409021 or placebo over the 12-week phase 2a study (A) and 24-week phase 2b study (B) treatment periods.Time course for LS mean (95% CI) change from baseline in fasting glucose level by week and treatment with LY2409021 or placebo over the 12-week phase 2a study (C) and 24-week phase 2b study (D) treatment periods. *P< 0.001 and †P< 0.05, compared with placebo. **P= 0.05, compared with placebo. Diabetes Care. 2016 Jul;39(7):1241-9. th> |
---|
LS mean (95% CI) change from baseline in SMBG level by time point and treatment with LY2409021 or placebo at end point week 12 (phase 2a study) (A) and week 24 (phase 2b study) (B). A: Time course for mean (±SE) change from baseline in ALT level (units/L) by week and treatment with LY2409021 or placebo over the 12-week phase 2a study treatment period. The ULNs for ALT level were 43 units/L (dashed line, male) and 34 units/L (dotted line, female).B: Time course for LS mean change (95% CI) from baseline in ALT level (units/L) by week and treatment with LY2409021 or placebo over the 24-week phase 2b study treatment period.Diabetes Care. 2016 Jul;39(7):1241-9. td> |
A: Time course for mean (±SE) change from baseline in fasting glucagon level (pmol/L) by week and treatment with LY2409021 or placebo over the 12-week phase 2a study treatment period.B: Time course for LS mean (95% CI) change from baseline in fasting glucagon level (pmol/L) by week and treatment with LY2409021 or placebo over the 24-week phase 2b study treatment period.C: Time course for mean (±SE) change from baseline in fasting total GLP-1 level (pmol/L) by week and treatment with LY2409021 or placebo over the 12-week phase 2a study treatment period.D: Time course for LS mean (95% CI) change from baseline in fasting total GLP-1 level (pmol/L) by week and treatment with LY2409021 or placebo over the 24-week phase 2b study treatment period.Diabetes Care. 2016 Jul;39(7):1241-9. td> |